Coronavirus vaccine could be ready this autumn, say Oxford University researchers behind major trial
- Oxford University researchers are confident they can roll out a jab in six months
- This ‘best case scenario’ is much sooner than the 12 to 18 month period touted
- More than 500 volunteers will begin tests this month, lasting until September
A coronavirus vaccine could be ready as early as autumn, leading scientists behind a major UK trial say.
Oxford University researchers are confident they can roll out a jab for the incurable disease within the next eight months.
This ‘best case scenario’ is much sooner than was previously touted. Britain’s chief scientific adviser said it would be at least 2021 until a vaccine was ready.
But the Oxford team, one of hundreds worldwide racing to develop a COVID-19 cure, warned it will be ‘challenging’ if the outbreak peaks before a jab is ready for trials.
With no tests available to identify who has already been infected it could be difficult to find unexposed people to take part in the trial, the researchers say.
More than 500 volunteers aged between 18 and 55 have signed up to the trial and will begin tests towards the end of the month.
Modelling by researchers at the University of Washington predicts Britain will hit its peak on April 17. So far the virus has killed 7,100 and infected 55,000 in the UK.
A coronavirus vaccine could be ready as early as autumn, Oxford University researchers say
But they warn the trial will be ‘challenging’ if the outbreak peaks before a jab is ready. So far the disease has killed 7,095 people in the UK
The researchers told The Telegraph: ‘The best-case scenario is that by the autumn of 2020 we have the results about the effectiveness of the vaccine from a phase III trial and the ability to manufacture large amounts of the vaccine.’
They admitted that this time frame was ‘highly ambitious’ many things could get in the way of that target.
Countries that have a widespread vaccination programme involving the Bacillus Calmette-Guérin (BCG) jab have a coronavirus death rate almost six times lower than nations that do not use it, a study reveals.
The BCG vaccine was invented a century ago and gives immunity to tuberculosis (TB) — a bacterial infection — but it is known to have other benefits.
Previous trials discovered people that receive the jab, which costs as little as £30, have improved immune systems and are able to protect themselves from infection.
For example, in a trial among Native Americans, BCG vaccination in childhood was able to offer protection against TB up to 60 years after vaccination.
The precise way this durable vaccine helps fend off other infections is relatively unknown but it may be by boosting the immune system’s innate mechanisms.
These so-called off-target effects include enhanced protection against respiratory diseases, and have been recognised by the World Health Organization (WHO).
The findings were published online on archive site medRxiv and not in a journal as the research has yet to be peer-reviewed — the process in which other academics scrutinise research.
The Johns Hopkins Bloomberg School of Public Health experts pooled publicly available data for the analysis.
An estimate on case fatality rate was produced from the best available data on mortality for the top 50 countries reporting highest case events.
‘At the moment it is not possible to identify who has already been infected, and if the virus is spreading quickly throughout the population it might be difficult to find unexposed people to take part in the trial.’
‘Conducting trials after the peak subsides presents another problem, because so many people will have developed a natural immunity by then, and the amount of transmission will have dropped so that those who are still not immune will take longer to be exposed to the virus.’
And the scientists warned they were still struggling to get funding to scale-up production of the potential drug so it can be issued to the masses.
Trial participants will take part in the study for six months, during which they’ll attend appointments at the Oxford Vaccine Centre for screening and vaccination.
They will be injected with either the new COVID-19 vaccine or a control jab.
Sir Patrick Vallance, the UK’s chief scientific adviser, previously said a vaccine was 12 to 18 months away from being developed and distributed to the masses.
It comes after the first group of Chinese volunteers who received potential coronavirus vaccinations are said to be healthy after finishing 14 days of quarantine.
Fourteen people returned home yesterday after participating in the first clinical trial for the vaccine candidate in Wuhan. A total of 18 out of the 108 participants have completed their medical observation as of Thursday.
The research team will monitor all the volunteers for another six months and take their blood samples to examine the antibodies.
Scientists have said that they plan to conduct additional trials overseas if the vaccine is proved to be effective and safe.
On March 17, China launched the clinical trials for its first potential coronavirus vaccine, which is developed by Chen Wei, the country’s top military bio-warfare expert, and her team.
The first group of Chinese volunteers who received potential coronavirus vaccinations have claimed to maintain good health after finishing two-week quarantine for observation
A total of 108 healthy adults, aged between 18 and 60, volunteered to receive the vaccinations. They were divided into three groups which were injected with different amounts of the vaccine, Chinese media report
A total of 108 healthy adults, aged between 18 and 60, volunteered to receive the vaccinations. They were divided into three groups which were injected with different amounts of the vaccine, Chinese media report.
The candidates have been isolated at the Wuhan Special Service Health Centre to monitor their condition. They will finish the medical observation on different days depending on when they were injected, according to the press.
‘My health has been absolutely fine during this period. I don’t feel sick or painful anywhere,’ a participant told Pear Video as he was leaving the facility yesterday.
‘There was a slight pain in where I was injected for the initial few days.
‘I feel very confident about the vaccine,’ he added. ‘I believe it will be introduced to the public very soon.’
Another volunteer told the press that she has returned to her daily life after ‘everything feels normal.’
‘It felt nothing different from receiving a regular injection, like being bitten by a mosquito,’ said Jin Guanping to Southern Metropolis daily.
The researchers said they would extend the vaccine tests internationally if the first trial proceeded smoothly.
‘If the initial results prove the vaccine is safe and produces [desired] effects, we will continue to test its effectiveness overseas through international cooperation if the global epidemic continues to spread,’ Chen Wei told the press.
The results of the clinical trial will be published in April, according to China Daily.
WHAT DO WE KNOW ABOUT THE CORONAVIRUS?
What is the coronavirus?
A coronavirus is a type of virus which can cause illness in animals and people. Viruses break into cells inside their host and use them to reproduce itself and disrupt the body’s normal functions. Coronaviruses are named after the Latin word ‘corona’, which means crown, because they are encased by a spiked shell which resembles a royal crown.
The coronavirus from Wuhan is one which has never been seen before this outbreak. It has been named SARS-CoV-2 by the International Committee on Taxonomy of Viruses. The name stands for Severe Acute Respiratory Syndrome coronavirus 2.
Experts say the bug, which has killed around one in 50 patients since the outbreak began in December, is a ‘sister’ of the SARS illness which hit China in 2002, so has been named after it.
The disease that the virus causes has been named COVID-19, which stands for coronavirus disease 2019.
Dr Helena Maier, from the Pirbright Institute, said: ‘Coronaviruses are a family of viruses that infect a wide range of different species including humans, cattle, pigs, chickens, dogs, cats and wild animals.
‘Until this new coronavirus was identified, there were only six different coronaviruses known to infect humans. Four of these cause a mild common cold-type illness, but since 2002 there has been the emergence of two new coronaviruses that can infect humans and result in more severe disease (Severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS) coronaviruses).
‘Coronaviruses are known to be able to occasionally jump from one species to another and that is what happened in the case of SARS, MERS and the new coronavirus. The animal origin of the new coronavirus is not yet known.’
The first human cases were publicly reported from the Chinese city of Wuhan, where approximately 11million people live, after medics first started publicly reporting infections on December 31.
By January 8, 59 suspected cases had been reported and seven people were in critical condition. Tests were developed for the new virus and recorded cases started to surge.
The first person died that week and, by January 16, two were dead and 41 cases were confirmed. The next day, scientists predicted that 1,700 people had become infected, possibly up to 7,000.
Where does the virus come from?
According to scientists, the virus almost certainly came from bats. Coronaviruses in general tend to originate in animals – the similar SARS and MERS viruses are believed to have originated in civet cats and camels, respectively.
The first cases of COVID-19 came from people visiting or working in a live animal market in Wuhan, which has since been closed down for investigation.
Although the market is officially a seafood market, other dead and living animals were being sold there, including wolf cubs, salamanders, snakes, peacocks, porcupines and camel meat.
A study by the Wuhan Institute of Virology, published in February 2020 in the scientific journal Nature, found that the genetic make-up virus samples found in patients in China is 96 per cent identical to a coronavirus they found in bats.
However, there were not many bats at the market so scientists say it was likely there was an animal which acted as a middle-man, contracting it from a bat before then transmitting it to a human. It has not yet been confirmed what type of animal this was.
Dr Michael Skinner, a virologist at Imperial College London, was not involved with the research but said: ‘The discovery definitely places the origin of nCoV in bats in China.
‘We still do not know whether another species served as an intermediate host to amplify the virus, and possibly even to bring it to the market, nor what species that host might have been.’
So far the fatalities are quite low. Why are health experts so worried about it?
Experts say the international community is concerned about the virus because so little is known about it and it appears to be spreading quickly.
It is similar to SARS, which infected 8,000 people and killed nearly 800 in an outbreak in Asia in 2003, in that it is a type of coronavirus which infects humans’ lungs. It is less deadly than SARS, however, which killed around one in 10 people, compared to approximately one in 50 for COVID-19.
Another reason for concern is that nobody has any immunity to the virus because they’ve never encountered it before. This means it may be able to cause more damage than viruses we come across often, like the flu or common cold.
Speaking at a briefing in January, Oxford University professor, Dr Peter Horby, said: ‘Novel viruses can spread much faster through the population than viruses which circulate all the time because we have no immunity to them.
‘Most seasonal flu viruses have a case fatality rate of less than one in 1,000 people. Here we’re talking about a virus where we don’t understand fully the severity spectrum but it’s possible the case fatality rate could be as high as two per cent.’
If the death rate is truly two per cent, that means two out of every 100 patients who get it will die.
‘My feeling is it’s lower,’ Dr Horby added. ‘We’re probably missing this iceberg of milder cases. But that’s the current circumstance we’re in.
‘Two per cent case fatality rate is comparable to the Spanish Flu pandemic in 1918 so it is a significant concern globally.’
How does the virus spread?
The illness can spread between people just through coughs and sneezes, making it an extremely contagious infection. And it may also spread even before someone has symptoms.
It is believed to travel in the saliva and even through water in the eyes, therefore close contact, kissing, and sharing cutlery or utensils are all risky. It can also live on surfaces, such as plastic and steel, for up to 72 hours, meaning people can catch it by touching contaminated surfaces.
Originally, people were thought to be catching it from a live animal market in Wuhan city. But cases soon began to emerge in people who had never been there, which forced medics to realise it was spreading from person to person.
What does the virus do to you? What are the symptoms?
Once someone has caught the COVID-19 virus it may take between two and 14 days, or even longer, for them to show any symptoms – but they may still be contagious during this time.
If and when they do become ill, typical signs include a runny nose, a cough, sore throat and a fever (high temperature). The vast majority of patients will recover from these without any issues, and many will need no medical help at all.
In a small group of patients, who seem mainly to be the elderly or those with long-term illnesses, it can lead to pneumonia. Pneumonia is an infection in which the insides of the lungs swell up and fill with fluid. It makes it increasingly difficult to breathe and, if left untreated, can be fatal and suffocate people.
Figures are showing that young children do not seem to be particularly badly affected by the virus, which they say is peculiar considering their susceptibility to flu, but it is not clear why.
What have genetic tests revealed about the virus?
Scientists in China have recorded the genetic sequences of around 19 strains of the virus and released them to experts working around the world.
This allows others to study them, develop tests and potentially look into treating the illness they cause.
Examinations have revealed the coronavirus did not change much – changing is known as mutating – much during the early stages of its spread.
However, the director-general of China’s Center for Disease Control and Prevention, Gao Fu, said the virus was mutating and adapting as it spread through people.
This means efforts to study the virus and to potentially control it may be made extra difficult because the virus might look different every time scientists analyse it.
More study may be able to reveal whether the virus first infected a small number of people then change and spread from them, or whether there were various versions of the virus coming from animals which have developed separately.
How dangerous is the virus?
The virus has a death rate of around two per cent. This is a similar death rate to the Spanish Flu outbreak which, in 1918, went on to kill around 50million people.
Experts have been conflicted since the beginning of the outbreak about whether the true number of people who are infected is significantly higher than the official numbers of recorded cases. Some people are expected to have such mild symptoms that they never even realise they are ill unless they’re tested, so only the more serious cases get discovered, making the death toll seem higher than it really is.
However, an investigation into government surveillance in China said it had found no reason to believe this was true.
Dr Bruce Aylward, a World Health Organization official who went on a mission to China, said there was no evidence that figures were only showing the tip of the iceberg, and said recording appeared to be accurate, Stat News reported.
Can the virus be cured?
The COVID-19 virus cannot be cured and it is proving difficult to contain.
Antibiotics do not work against viruses, so they are out of the question. Antiviral drugs can work, but the process of understanding a virus then developing and producing drugs to treat it would take years and huge amounts of money.
No vaccine exists for the coronavirus yet and it’s not likely one will be developed in time to be of any use in this outbreak, for similar reasons to the above.
The National Institutes of Health in the US, and Baylor University in Waco, Texas, say they are working on a vaccine based on what they know about coronaviruses in general, using information from the SARS outbreak. But this may take a year or more to develop, according to Pharmaceutical Technology.
Currently, governments and health authorities are working to contain the virus and to care for patients who are sick and stop them infecting other people.
People who catch the illness are being quarantined in hospitals, where their symptoms can be treated and they will be away from the uninfected public.
And airports around the world are putting in place screening measures such as having doctors on-site, taking people’s temperatures to check for fevers and using thermal screening to spot those who might be ill (infection causes a raised temperature).
However, it can take weeks for symptoms to appear, so there is only a small likelihood that patients will be spotted up in an airport.
Is this outbreak an epidemic or a pandemic?
The outbreak was declared a pandemic on March 11. A pandemic is defined by the World Health Organization as the ‘worldwide spread of a new disease’.
Previously, the UN agency said most cases outside of Hubei had been ‘spillover’ from the epicentre, so the disease wasn’t actually spreading actively around the world.
Source: Read Full Article